A Phase 1 interventional study of nab-sirolimus in Pulmonary Hypertension, sponsored by Aadi Bioscience, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Aadi Bioscience, Inc. · Phase 1, Interventional, and Treatment
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. nab-Sirolimus (also known as ABI-009, nab-rapamycin) is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.
nab-Sirolimus, an mTOR inhibitor, is a novel formulation of albumin-bound sirolimus nanoparticles and has produced encouraging results in oncology at doses up to 100 mg/m2 given once weekly IV. This study is aimed to determine the optimal clinial dose of once weekly IV nab-sirolimus in patients with PAH and safety of 16 weeks of therapy (Phase 1, Dose finding Safety Part) followed optionally by up to 32 weeks of therapy (Extension Part).
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
This study's enrollment of 15 is below the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →Aadi Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet following hemodynamic definition prior to initiation of study drug
Meet the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to screening, performed with or without bronchodilation:
Exclusion criteria:
Baseline cytopenias:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nab-Sirolimus Dose Cohort 1 at 10 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
Drug: nab-sirolimus
nab-Sirolimus Dose Cohort 2 at 1.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
Drug: nab-sirolimus
nab-Sirolimus Dose Cohort 3 at 2.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
Drug: nab-sirolimus
nab-Sirolimus Dose Cohort 4 at 5.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
Drug: nab-sirolimus
nab-Sirolimus Dose Cohort 5 at 7.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)
Drug: nab-sirolimus
nab-sirolimus is an mTOR inhibitor
Also known as: ABI-009, nab-rapamycin
Dose-limiting Toxicities
A dose-limiting toxicity (DLT) was defined as a study drug-related Grade ≥3 hematologic AE or persistent intolerable nonhematologic AE of any grade that occurred during the first 4 weeks of treatment, requiring dose reduction or permanent discontinuation of the study drug, in the opinion of the Investigator. The number and percent of patients with a DLT were to be reported by dose cohorts in the Phase 1 dose finding part of the study if any were observed in the study.
Time frame: 16 weeks
Right Heart Catheterization Based on Central Lab Analysis (Pulmonary Vascular Resistance, Cardiac Output, Cardiac Index, Stroke Volume)
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in RHC based on Central Lab Analysis (Pulmonary vascular resistance, Cardiac Output, Cardiac Index, Stroke Volume)
Time frame: 17 Weeks
6-minute Walk Distance (6MWD)
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in 6MWD
Time frame: 17 Weeks
N-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP)
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in NT Pro-BNP
Time frame: 17 Weeks
| Milestone | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 |
|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 3 | 1 |
| Completed | 3 | 3 | 4 | 2 | 1 |
| Not completed | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 risk | 0 | 0 | 0 | 1 | 0 |
| Milestone | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 |
|---|---|---|---|---|---|
| Started | 0 | 1 | 4 | 1 | 1 |
| Completed | 0 | 1 | 2 | 1 | 0 |
| Not completed | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 |
A dose-limiting toxicity (DLT) was defined as a study drug-related Grade ≥3 hematologic AE or persistent intolerable nonhematologic AE of any grade that occurred during the first 4 weeks of treatment, requiring dose reduction or permanent discontinuation of the study drug, in the opinion of the Investigator. The number and percent of patients with a DLT were to be reported by dose cohorts in the Phase 1 dose finding part of the study if any were observed in the study.
| Participants | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 |
|---|---|---|---|---|---|
| Dose-limiting Toxicities | 0 | 0 | 0 | 0 | 0 |
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in RHC based on Central Lab Analysis (Pulmonary vascular resistance, Cardiac Output, Cardiac Index, Stroke Volume)
| percentage of change | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Overall |
|---|---|---|---|---|---|---|
| Pulmonary Vascular Resistance (dyn×sec/cm5) | -30.1 (-47.8 to -21.8) | 10.9 (-20.5 to 18.0) | -3.5 (-40.2 to 14.5) | -15.7 (-33.3 to 1.9) | -30.8 (-30.8 to -30.8) | -20.5 (-47.8 to 18.0) |
| Thermodilution Cardiac Output Mean (L/minute) | 40.1 (39.5 to 59.6) | -15.4 (-23.1 to -13.1) | 10.8 (-15.6 to 40.1) | 9.6 (-9.4 to 28.5) | 27.4 (27.4 to 27.4) | 16.9 (-23.1 to 59.6) |
| Cardiac Index (L/minute/m2) | 40.1 (39.5 to 66.4) | -16.5 (-17.4 to -12.8) | 13.5 (-17.2 to 43.9) | 9.4 (-5.7 to 24.5) | 31.2 (31.2 to 31.2) | 21.4 (-17.4 to 66.4) |
| Stroke Volume (mL) | 11.6 (11.1 to 81.1) | -14.4 (-19.4 to 10.3) | 11.0 (-24.6 to 42.3) | 6.3 (-14.6 to 27.1) | 10.5 (10.5 to 10.5) | 10.5 (-24.6 to 81.1) |
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in 6MWD
| percentage of change | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Overall |
|---|---|---|---|---|---|---|
| 6-minute Walk Distance (6MWD) | -2.0 (-21.0 to 46.6) | 16.0 (3.1 to 37.8) | 13.3 (-14.0 to 22.5) | 16.6 (12.3 to 21.0) | 21.0 (21.0 to 21.0) | 15.0 (-21.0 to 46.6) |
Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in NT Pro-BNP
| percentage of change | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Overall |
|---|---|---|---|---|---|---|
| N-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP) | -49.0 (-65.5 to 79.7) | -34.6 (-73.8 to -4.5) | -7.1 (-62.2 to 18.8) | -10.8 (-21.6 to 0.0) | -17.0 (-17.0 to -17.0) | -19.3 (-73.8 to 79.7) |
Collected over Adverse Events reported in the initial 16-Week Treatment for all Cohorts 1,2,3,4 & 5 (ie, from baseline through Week 16). Adverse Events reported in the Optional Extension Phase for up to additional 32 weeks of treatment for Cohorts 2, 3, 4, and 5 (ie, Week 17 through 48).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nab-Sirolimus Dose Cohort 1 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Nab-Sirolimus Dose Cohort 2 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Nab-Sirolimus Dose Cohort 3 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Nab-Sirolimus Dose Cohort 4 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Nab-Sirolimus Dose Cohort 5 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Overall Nab-Sirolimus Dose Cohort 1-5 | 0/15 (0%) | 2/15 (13.3%) | 15/15 (100%) |
| Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional Extension | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Nab-Sirolimus Dose Cohort 3; 32 Weeks Optional Extension | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Nab-Sirolimus Dose Cohort 4; 32 Weeks Optional Extension | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Nab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Overall Nab-Sirolimus Dose Cohort 1-5 | Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 3; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 4; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension |
|---|---|---|---|---|---|---|---|---|---|---|
| Pneumonia bacterialInfections and infestations | 0/4 | 0/3 | 0/4 | 1/3 | 0/1 | 1/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| Pneumonia viralInfections and infestations | 0/4 | 0/3 | 0/4 | 1/3 | 0/1 | 1/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| CellulitisInfections and infestations | 1/4 | 0/3 | 0/4 | 0/3 | 0/1 | 1/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| Device Related InfectionInfections and infestations | 0/4 | 0/3 | 0/4 | 0/3 | 0/1 | 0/15 | 0/1 | 1/4 | 0/1 | 0/1 |
| Event | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Overall Nab-Sirolimus Dose Cohort 1-5 | Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 3; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 4; 32 Weeks Optional Extension | Nab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension |
|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/4 | 1/3 | 0/4 | 3/3 | 1/1 | 7/15 | 0/1 | 1/4 | 0/1 | 0/1 |
| HeadacheNervous system disorders | 2/4 | 3/3 | 1/4 | 2/3 | 1/1 | 9/15 | 0/1 | 1/4 | 0/1 | 0/1 |
| RashSkin and subcutaneous tissue disorders | 2/4 | 1/3 | 1/4 | 2/3 | 1/1 | 7/15 | 0/1 | 0/4 | 1/1 | 0/1 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/4 | 1/3 | 1/4 | 0/3 | 1/1 | 3/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| HypertriglyceridemiaMetabolism and nutrition disorders | 2/4 | 1/3 | 0/4 | 0/3 | 1/1 | 4/15 | 0/1 | 0/4 | 1/1 | 0/1 |
| Dry MouthGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 1/3 | 1/1 | 2/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| OnychoclasisSkin and subcutaneous tissue disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/1 | 0/15 | 0/1 | 0/4 | 0/1 | 1/1 |
| DiarrheaGastrointestinal disorders | 3/4 | 1/3 | 1/4 | 2/3 | 0/1 | 7/15 | 0/1 | 0/4 | 0/1 | 0/1 |
| InfectionInfections and infestations | 1/4 | 0/3 | 1/4 | 1/3 | 0/1 | 3/15 | 0/1 | 3/4 | 0/1 | 0/1 |
| FatigueGeneral disorders | 1/4 | 1/3 | 1/4 | 2/3 | 0/1 | 5/15 | 0/1 | 0/4 | 0/1 | 0/1 |
The safety analysis set includes all treated patients
| Age, Continuous(years) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Median | 56.5 (52 to 69) | 45 (44 to 63) | 38.5 (20 to 67) | 45 (44 to 67) | 28 (28 to 28) | 45 (20 to 69) |
| Sex: Female, Male(Participants) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| 16-Week Dose-finding Safety Part — Female | 3 | 3 | 4 | 3 | 1 | 14 |
| 16-Week Dose-finding Safety Part — Male | 1 | 0 | 0 | 0 | 0 | 1 |
| 32-Week Optional Extension Part — Female | 0 | 1 | 4 | 1 | 1 | 7 |
| 32-Week Optional Extension Part — Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| 16-Week Dose-finding Safety Part — Hispanic or Latino | 0 | 1 | 1 | 1 | 0 | 3 |
| 16-Week Dose-finding Safety Part — Not Hispanic or Latino | 4 | 2 | 3 | 2 | 1 | 12 |
| 16-Week Dose-finding Safety Part — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — Hispanic or Latino | 0 | 1 | 2 | 0 | 0 | 3 |
| 32-Week Optional Extension Part — Not Hispanic or Latino | 0 | 0 | 2 | 1 | 1 | 4 |
| 32-Week Optional Extension Part — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| 16-Week Dose-finding Part — American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| 16-Week Dose-finding Part — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| 16-Week Dose-finding Part — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| 16-Week Dose-finding Part — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| 16-Week Dose-finding Part — White | 4 | 3 | 3 | 3 | 1 | 14 |
| 16-Week Dose-finding Part — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| 16-Week Dose-finding Part — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| 32-Week Optional Extension Part — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — White | 0 | 1 | 3 | 1 | 1 | 6 |
| 32-Week Optional Extension Part — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| 32-Week Optional Extension Part — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| United States | 4 | 3 | 4 | 3 | 1 | 15 |
| Body Surface Area(m^2) | Nab-Sirolimus Dose Cohort 1 | Nab-Sirolimus Dose Cohort 2 | Nab-Sirolimus Dose Cohort 3 | Nab-Sirolimus Dose Cohort 4 | Nab-Sirolimus Dose Cohort 5 | Total |
|---|---|---|---|---|---|---|
| 16-Week Dose-finding Safety Part | 2.1 (1.5 to 2.5) | 1.6 (1.5 to 1.7) | 1.6 (1.5 to 1.9) | 1.8 (1.5 to 1.9) | 1.8 (1.8 to 1.8) | 1.7 (1.5 to 2.5) |
| 32-Week Optional Extension Part | — | 1.5 (1.5 to 1.5) | 1.7 (1.5 to 1.9) | 1.9 (1.9 to 1.9) | 1.8 (1.8 to 1.8) | 1.8 (1.5 to 1.9) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Aug 2022, 64 months.
Results were first posted in Nov 2024, 2 years 3 months after primary completion.
Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 64 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus Albumin-bound Nanoparticles
Aadi Bioscience, Inc.